Tidal Care Inc.

Name

Tidal Care Inc.

Legal name

Tidal Care Inc.

Website

https://tidalcare.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Psychedelic Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• GMP psilocybin products
• Psychedelic raw materials
• Psilocybin cultivation services
• Clinical psilocybin supply
• Psychedelic therapeutics supply

Headquarters

HQ city

Edmonton

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Licensed Supply of GMP Psilocybin Products: The primary revenue stream involves supplying GMP-grade psilocybin products to licensed clinical facilities and special access program applications. Products are distributed to healthcare providers and treatment centers for psychedelic-assisted therapy.
2. Research and Development Services: Academic partnerships with universities (Guelph, Loyalist College, Toronto) may generate revenue through collaborative research agreements and product development services.
3. Investment Capital: The company is in second round of seed funding, raising capital from investors to accelerate production timeline and market development in the psychedelic therapeutics sector.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Tidal Care Inc. develops and supplies GMP-certified psilocybin raw materials and processed products for clinical applications, special access programs, and research/treatment applications. The company cultivates proprietary variants of Psilocybe Cubensis mushrooms using novel cultivation methods developed through a research alliance with the University of Guelph, producing high-quality therapeutic materials for licensed healthcare facilities across multiple regulatory jurisdictions.

Product overview

Tidal Care Inc. operates as a B2B supplier in the psychedelics industry, providing high-quality GMP psilocybin products including proprietary Psilocybe Cubensis mushroom variants for clinical and research applications. The company functions as a raw materials and processed products provider for regulatory jurisdictions and treatment applications, with therapeutic products and high-compliance services as its core offering.

Differentiator

Problem solved

Functional benefit

Products and services

• GMP Psilocybin Products High-quality GMP-certified psilocybin raw materials and processed products suitable for clinical applications, special access programs, and research/treatment applications across various regulatory jurisdictions. Products are supplied to licensed healthcare facilities, treatment providers, and research institutions for psychedelic-assisted mental health therapies addressing PTSD, addiction, depression, and anxiety.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• University of TorontominorStrategic or Co-development Partner · 13 October 2023Internship collaboration providing students with psychedelic industry experience while enabling Tidal to access emerging talent in the field.
• Loyalist CollegeminorStrategic or Co-development Partner · 1 September 2023Research collaboration with Loyalist College for psychedelic therapy research and development initiatives.
• University of GuelphcoreStrategic or Co-development Partner · 11 July 2023Research Alliance with University of Guelph featuring Dr. Max Jones (Ph.D.) with Health Canada Controlled Drugs and Substances License for cultivation and processing of psilocybin materials, and Dr. Gale Bozzo (Ph.D.) providing analytical chemistry expertise for post-harvest analysis and quality validation of proprietary Psilocybe Cubensis variants.
• Neuromed CliniccoreStrategic or Co-development PartnerPartnership with Edmonton-based Neuromed Clinic offering Ketamine Treatment and MeRT & TMS Treatment services. Clinic staff received specialist training at Harvard University and Duke University, and established Edmonton's first TMS service in 2017. Partnership positioned for potential future psilocybin treatment integration.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and alternative therapies for mental health. Comparable psychedelic therapeutics developer with portfolio approach and GMP-grade product development serving similar indications.
• Filament Health Corp. Canadian-based natural psilocybin drug development company producing pharmaceutical-grade botanical psilocybin. Direct comparable as a GMP-grade psilocybin API supplier serving clinical and research applications with comparable product positioning.
• Numinus Wellness: Canadian psychedelic therapy company operating clinics and licensed psilocybin production. Direct peer in the Canadian market combining clinical service delivery with GMP-grade psychedelic product supply, mirroring Tidal Care's B2B/GMP focus.
• Cybin Inc. Canadian-based psychedelic pharmaceutical company developing psilocybin-based therapies. Highly comparable as another Canadian-domiciled psilocybin developer with GMP-focused operations serving clinical applications, although Cybin is more drug-development oriented.
• Optimi Health Corp. Canadian psychedelics manufacturer producing GMP psilocybin and MDMA at Health Canada-licensed facilities. Direct peer in Canadian GMP psychedelic production for clinical and research markets with similar regulatory positioning.
• GH Research PLC: Ireland-based clinical-stage company developing GMP psilocybin therapy for treatment-resistant depression. Comparable as a regulated GMP psilocybin manufacturer serving mental health clinical applications.
• Compass Pathways plc: UK-based clinical-stage company developing psilocybin therapy for treatment-resistant depression. Comparable as a leading developer and supplier of GMP psilocybin for clinical trials, with regulatory-grade product formulation.
• Mind Medicine (MindMed) Inc. Clinical-stage psychedelic medicine developer focused on psilocybin and LSD-based therapies for mental health. Comparable psychedelic therapeutics company with regulatory-grade psychedelic product development for PTSD, anxiety, and addiction - Tidal Care's target indications.
• Revive Therapeutics Ltd. Canadian specialty psychedelic pharmaceutical company focused on psilocybin-based therapeutics. Comparable Canadian peer pursuing psilocybin for neurological disorders and mental health, with similar GMP-supply positioning.

Emerging players

• Field Trip Health & Wellness: Canadian-origin psychedelic-assisted therapy provider with treatment clinics. Closely comparable Canadian-domiciled mental health psychedelic player, although focused on clinic delivery rather than API supply like Tidal Care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tidal-care-inc
• Instagraminstagram.com/tidalcareinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tidal Care Inc.